Uniwersytet Warszawski

Instytut Farmakologii Polskiej Akademii Nauk

Ewa Witkowska

Aleksandra Misicka-Kesik

Piotr Sosnowski

Bartlomiej Fedorczyk

Beata Wilenska

Dagmara Tymecka

Anna Starzec

Joanna Mika

Anna Niescioruk

Joanna Starnowska-Sokol

Anna Piotrowska-Murzyn

Aleksandra Misicka-Kęsik

Gerard Y Perret

Anna Puszko

Beata Wileńska

Barbara Przewlocka

Karolina Grabowska

Patrick Ladam

The invention pertains to novel hybrid peptidomimetics, pharmaceutical composition comprising thereof and use thereof in the treatment of neuropathic pain. The hybrid peptidomimetics according to the invention are comprised of two components: an opioid receptor agonist (OP) and a MC4 receptor antagonist, connected by a linker. The compounds of such a structure will allow to activate opioid receptors with simultaneous blocking of melanocortin type 4 receptors (MC4), which results in enhancing efficiency of the opioid therapy in neuropathic pain.

Hybrid peptidomimetics for use in neuropathic pain

The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, diabetes, degenerative diseases of the eye (ARMD), nephropathy and neuropathy.

Cyclic peptidomimetics, compositions containing them and their use in the treatment of diseases associated with angiogenesis

We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (ARMD), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.

Peptidomimetics with antiangiogenic activity

Growing community of inventors

Zielonka, Poland

Ewa Witkowska